**Vaccine supply is limited and it will take time to vaccinate everyone. Thank you for your patience as the State rolls out more vaccines every week. Currently, all adults over the age of 16 are eligible to receive the vaccination.**
The Texas Department of State Health Services (DSHS) is prioritizing large vaccination hubs across the state to distribute COVID-19 vaccines from the federal government. The City of Rowlett and other nearby cities will assist by providing resources that may be needed to distribute the vaccinations.
Garland Health Authority, along with Dallas, Rockwall, Collin, Denton, and Tarrant counties have opened online vaccine registration for individuals wishing to receive a vaccination at one of the DSHS hubs. Links are provided below for the online registration for each county. Due to the statewide effort, each county that is distributing the vaccine may approach the process differently and may provide different types of vaccines. There is no city or county residency requirement to register to receive a vaccination at one of the official hub sites, these sites are open to all Texas residents. People who register will be placed on a waitlist and will be provided further guidance at a later date as to when to arrive to receive a vaccination.
CALL 2-1-1 for providers if you know someone who is eligible for a vaccine but doesn’t have internet access.
VIEW our COVID-19 Vaccine Frequently Asked Questions for more information!
VISIT dshs.texas.gov/coronavirus/immunize/vaccine-hubs.aspx for more information on the operation of statewide vaccination sites and hubs and to find additional providers (pharmacies, healthcare facilities, etc.).
Sign up for V-safe after you get vaccinated! V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination.
Pfizer, the first COVID-19 vaccine granted an Emergency Use Authorization (EUA) in the US, has begun a clinical trial for children aged 12-15 years, and has begun planning for a trial for children aged 5 to 11 years later this year. Additionally, Moderna has begun a clinical trial for children ages 12-17. Moderna has also begun testing a booster vaccine for potential use against COVID-19 variant strains.
Novavax has also released data on their COVID-19 vaccine candidate, showing 89% efficacy against moderate and severe COVID-19 disease. They are also manufacturing an additional potential booster or supplement dose for variant strains of COVID-19. Novavax has applied for approval in the UK, and is working with the FDA to submit for an EUA.
AstraZeneca’s vaccine has been approved for emergency use in the European Union, but has not yet been approved in the United States. Thus far, the vaccine has shown 82% efficacy after two doses, however, many countries are advising that this vaccine is not given to individuals over the age of 65, due to a lack of data surrounding this age group.